discuss

FlightHub and JustFly Discuss What the Deal is With Price Fluctuations on Flights

Press Release – updated: Nov 15, 2019 12:33 EST

SEATTLE, November 15, 2019 (Newswire.com) – Travelers often wonder why the price posted for one seat on an airplane – for example, an aisle seat near an emergency exit that offers extra legroom – changes so much and so unpredictably. FlightHub and JustFly, top online travel companies, help demystify this.
If travelers saw it plotted on a graph, they would notice the price of one seat fluctuates as often as a dozen times, not unlike a stock trading on an exchange. This is because seat prices are often at the mercy of market conditions, as well as other factors.
If a flight seat is like a stock, when is the best time to buy?
When travelers use an online travel agency (OTA) site to assist them in finding deals on flights, they are counting on its process and complex algorithms for amalgamating flight data and prices worldwide. Each one filters and presents the details of this data in its own way.
Low ticket prices for those who book early
Seat sales to popular destinations, like Caribbean resorts, begin months in advance. They’re priced low for those who think ahead, so there’s nothing wrong with a plan-well-in-advance travel strategy. A think-ahead kind of person can feel confident that the deal they find three months in advance is a reasonable one. Now, they only have to ask for vacation time.
Riding the seat-price roller coaster leading up to the departure date
If travelers miss the initial low promo prices for, let’s say, a ticket to L.A., then they will be left to watch the price on flights to the City of Angels on their departure date fluctuate until the plane takes off.
When the first lower-priced group of tickets sells out, the next group goes up in price and so on. Each time a ticket changes, the information passes almost instantaneously to global distribution systems, where it’s picked up by travel agents and online travel agents to get to the traveler.
The sweet spot for less-organized flyers
As the date of take-off arrives, travelers can count on prices slowly creeping higher as a flight gradually gets booked. However, it’s not unusual for an airline to interject, for any number of promotional reasons, a price drop, somewhere along this timeline.
Last-minute changes in flight prices
When travelers are booking two weeks or just days in advance, their chances of finding a deal are much slimmer, particularly if they are traveling at a rush period like Christmas or summer holidays.
“Crunch time is exactly the time when our online travel agencies, who access all the airlines flying to Montreal, or countless other destinations, on the desired departure day can save travelers hundreds of dollars,” states FlightHub and JustFly’s Matt Keezer. “Our complex algorithms take care of finding the lowest prices, so all travelers must worry about is what to pack”.
For further information: please contact us by email at media@flighthub.com
Source: FlightHub

Dr. Jeremy Friese of Verata Health Invited to Discuss the State of Prior Authorizations with Minnesota Hospital Association and North Memorial Health Leadership

Dr Jeremy Friese

“I’m proud that our proven artificial intelligence platform is helping patients across the country and providing immediate financial value for providers,” said Dr. Friese.

MINNEAPOLIS (PRWEB) November 06, 2019
Faced with growing prior authorization burden across the state of Minnesota the Minnesota Hospital Association announced a webinar with Dr. Jeremy Friese, CEO of Verata Health, Matt Anderson, Interim CEO of Minnesota Hospital Association, and Nate Dell, VP of Revenue Cycle Management at North Memorial Health to understand the current challenges faced by Minnesota providers and potential solutions. Joe Schindler, VP of Finance of Minnesota Hospital Association, will moderate the webinar to be held on Wednesday, November 6 at noon CST.
Hosted by the Minnesota Hospital Association, the webinar will provide an update on Prior Authorization (PA) advocacy efforts in Minnesota as well as highlight the ways in which Minnesota hospitals and health systems are working to reduce patient delays and billing denials related to PA challenges. Best practices and transformational improvements to PA processes using artificial intelligence will also be discussed.
Manual, time-consuming prior authorizations are a major bottleneck for medical care, leading to delays in obtaining necessary tests and procedures for patients. According to the American Medical Association, 92 percent of physicians report patient care delays due to PA. For clinics and hospitals, the impact is also financial. In recent years, errors in prior authorizations have grown to account for 30% of all provider write-offs. Industry experts quote a cost of $20-50 per prior authorization and tens of thousands more per physician annually due to expensive write-offs. By leveraging powerful artificial intelligence, Verata Health’s provider and hospital customers across the country are automating both simple and complex prior authorizations, dramatically reducing staff burden, increasing patient throughput and reducing costly write-offs.
“After spending nearly two decades practicing medicine and helping lead the most profitable department at Mayo Clinic, I launched Verata Health to help patients get the care they deserve by solving the national PA problem. I’m proud that our proven artificial intelligence platform is helping patients across the country and providing immediate financial value for providers,” said Dr. Friese.
About Verata Health:Verata Health is a Minnesota-based, physician-led company changing the way medical practices and hospitals tackle the challenges presented by obtaining prior authorization (PA). By leveraging powerful artificial intelligence, Verata Health automates both simple and complex prior authorizations thereby delivering immediate financial value and most importantly helping patients get the care they deserve. For more information please visit http://www.veratahealth.com.

Share article on social media or email:

Catalent to Discuss the Future of Cell and Gene Therapy Manufacturing at World Orphan Drug Congress Europe

SOMERSET, N.J. (PRWEB) November 05, 2019
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced it will present at the upcoming World Orphan Drug Congress Europe, being held at Hotel Sofia, Barcelona, Spain on Nov. 12 – 14, 2019.
On Wednesday, Nov. 13 at 3:20 p.m., Philip Wills, Ph.D., Chief Commercial Officer, Paragon Gene Therapy (part of Catalent Biologics) will present “Capacity Crunch? The Future of Manufacturing Within Cell & Gene Therapy” as part of the manufacturing track. Dr. Wills’ presentation will highlight the challenges that the gene therapy sector faces in scale-up and manufacturing, driven by the rising numbers of clinical trials and FDA approvals, coupled with low product yields and rising treatment costs. These factors have led to an increased demand for process expertise and manufacturing capacity, and Dr. Wills will address the capacity limitations and discuss the future of cell and gene therapy manufacturing.
Also, on Wednesday, at 2:20 p.m., Stephen Tindal, Director, Science & Technology and Gavin Yates, Program Director, Clinical Supply Services and Drug Product Technologies Integrations, will discuss the benefits of contracting with a single, integrated provider in their presentation, “Next Exit, Success: Get from Concept to Clinic Faster on the Product Development Superhighway.” In the presentation, Mr. Tindal and Mr. Yates will highlight opportunities to streamline and shorten product development timelines.
Dr. Wills has almost two decades of contract manufacturing experience, primarily focused in viral vectors and other complex biologics. He joined Paragon in 2002 where he has since held positions of increasing scope and responsibility, including as Principal Scientist and Vice President of Business Development. He received a bachelor’s degree in chemistry from John Hopkins University, Baltimore, Maryland, and a doctorate in pharmacology from University of Maryland Medical School, Maryland.
Mr. Tindal has worked in softgel R&D for more than 30 years and has broad expertise in this technology. He specializes in root cause investigation, technology innovation, gelatin innovation, and plays a key role in customer liaison and supporting business development. Mr. Tindal holds a bachelor’s degree in chemistry and analytical science from Loughborough University, U.K.
Mr. Yates has more than 15 years’ experience in the pharmaceutical industry. His areas of expertise include project management, packaging and labeling, operational activity, supply chain management and key performance indicator (KPI) analysis. He received his bachelor’s degree in biological sciences from University of Birmingham, U.K.
For more information, visit https://www.catalent.com/index.php/news-events/events/World-Orphan-Drug-Congress-Europe.
To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR – richard@nepr.agency.
About CatalentCatalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.
More products. Better treatments. Reliably supplied.™

Share article on social media or email: